Cancer Drug Pipeline Information for Patient Advocacy … advised that the information contained in...

Brand Name Generic Name Manufacturer Indication Route of

Administration

Information Source

Breast Cancerabemaciclib Eli Lilly Breast cancer - Phase 2 Oral http://lillyoncologypipeline.com/clinical-phase/II

abemaciclib Eli Lilly Breast cancer - Phase 3 Oral http://lillyoncologypipeline.com/clinical-phase/III

alpelisib Novartis Breast cancer Phase 2 Oral https://www.novartisoncology.com/about-us/our-pipeline

alpelisib Novartis Breast cancer Phase 3 Oral https://www.novartisoncology.com/about-us/our-pipeline

Tecentriq atezolizumab Hoffman-La RocheMetastatic triple-negative breast cancer, first-line

treatmentIntravenous

http://www.roche.com/research_and_development/who_we_are_h

ow_we_work/pipeline.htm

AZD5363 AstraZeneca Breast cancer https://www.astrazeneca.com/our-focus-areas/oncology.html

Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-negative Intravenous http://www.gene.com/medical-professionals/pipeline

Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-postive Intravenous http://www.gene.com/medical-professionals/pipeline

buparlisib Novartis Breast cancer Phase 2 Oral https://www.novartisoncology.com/about-us/our-pipeline

Cometriq cabozantinib Exelixis Breast cancer: patients with brain metastases Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli

nical%20Trials%20-%20November%202016.pdf

Cometriq cabozantinib ExelixisBreast cancer: metastatic, hormone-receptor

positiveOral

http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


Cotellic cobimetinib Hoffman-La Roche First line metastatic triple negative breast cancer Oralhttp://www.roche.com/research_and_development/who_we_are_h


Xgeva denosumab AmgenDelay or prevention of bone metastases in

patients with adjuvant breast cancerSubcutaneous http://www.amgenpipeline.com/pipeline/

Xtandi enzalutamide Pfizer Triple-negative breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-

pipeline/PfizerPipeline_1.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use

of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please

be advised that the information contained in this document is not a comprehensive list. Please contact [email protected] with any inquiries about the information contained in this document.

Cancer Drug Pipeline Information for Patient Advocacy Groups

Last updated: December 1, 2016

© Canadian Cancer Action Network 2016 1

http://lillyoncologypipeline.com/clinical-phase/II

http://lillyoncologypipeline.com/clinical-phase/III

https://www.novartisoncology.com/about-us/our-pipeline


http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm


https://www.astrazeneca.com/our-focus-areas/oncology.html

http://www.gene.com/medical-professionals/pipeline





http://www.amgenpipeline.com/pipeline/


Administration

Information Source




Xtandi enzalutamide Pfizer ER/PR+ & HER2-normal breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Xtandi enzalutamide Pfizer AR+, HER2+ amplified breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Xtandi enzalutamide Astellas Pharma Triple-negative breast cancer Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Xtandi enzalutamide Astellas Pharma Breast cancer (ER/PgR positive, HER2 positive) Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Halaven eribulin Eisai Breast cancer Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

ipatasertib Genentech Triple-negative breast cancer Oral http://www.gene.com/medical-professionals/pipeline

Masivet masitinib AB ScienceRealpsed metastatic non-triple negative breast

cancerOral

http://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Masivet masitinib AB Science Relapsed metastatic triple negative breast cancer Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

MCS110 Novartis Breast cancer https://www.novartisoncology.com/about-us/our-pipeline

MEDI-573 AstraZeneca Metastatic breast cancer https://www.astrazeneca.com/our-focus-areas/oncology.html

neratinib Puma

Metastatic HER2 non-amplified but HER2 mutant

breast cancer, alone and in combination with

fulvestrant

Oral https://clinicaltrials.gov/show/NCT01670877

oral azacitidine (CC-

486)Celgene Metastatic breast cancer Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Abraxane paclitaxel Celgene First-line metastatic triple-negative breast cancer Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf




https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf


http://www.ab-science.com/en/human-medicine/masitinib-in-oncology






https://clinicaltrials.gov/show/NCT01670877

https://www.celgene.com/content/uploads/product-pipeline.pdf



Administration

Information Source




Abraxane paclitaxel Celgene Metastatic breast cancer Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Ibrance palbociclib Pfizer Recurrent advanced breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Ibrance palbociclib Pfizer Early breast cancer in adjuvant setting Oralhttp://www.pfizer.com/sites/default/files/product-


Ibrance palbociclib Pfizer

For the treatment of women with hormone

receptor (HR)-positive, human epidermal growth

factor receptor 2 (HER2)-negative advanced or

metastatic breast cancer with disease progression

following endocrine therapy in combination with

fulvestrant

Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m487080.htm

Ibrance palbociclib Pfizer High-risk early breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Keytruda pembrolizumab Merck Breast cancer Intravenous http://www.merck.com/research/pipeline/home.html

Perjeta pertuzumab Hoffman-La Roche Early HER2-positive breast cancer Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Perjeta pertuzumab Genentech Early HER2-positive breast cancer Intravenous http://www.gene.com/medical-professionals/pipeline

Perjeta pertuzumab Genentech 2nd line HER2-negative breast cancer Intravenous http://www.gene.com/medical-professionals/pipeline

ribociclib Novartis Breast cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

ribociclib NovartisHR+ HER2- advanced breast cancer in pre and

postmenopausal womenOral https://www.novartisoncology.com/about-us/our-pipeline

SERD (GDC-0810) Genentech ER+ HER2-ngeative breast cancer Oral http://www.gene.com/medical-professionals/pipeline

TAK-228 Takeda Breast cancer Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-

Oncology-Pipeline.pdf




http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf




http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm










Administration

Information Source




talazoparib Pfizer Germline BRCA-mutated metastatic breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-


taselisibHoffmann-La

Roche

HER2-negative, hormone receptor-positive

metastatic breast cancer, neoadjuvant treatmentOral



taselisib Hoffman-La RocheHER2-negative, hormone receptor-positive

metastatic breast cancerOral



Kadcylatrastuzumab

emtansineGenentech 1st line HER2-positive metastatic breast cancer Intravenous http://www.gene.com/medical-professionals/pipeline

Kadcylatrastuzumab

emtansine

Hoffmann-La

Roche

Second line HER2-positive metastatic breast

cancer, in combination with TecentriqIntravenous



Kadcylatrastuzumab

emtansine

Hoffmann-La

RocheThrid-line HER2-positive metastatic breast cancer Intravenous



Kadcylatrastuzumab

emtansineGenentech 3rd line HER2-positive metastatic breast cancer Intravenous http://www.gene.com/medical-professionals/pipeline

Kadcylatrastuzumab

emtansineHoffman-La Roche

Early HER2-positive breast cancer, adjuvant

treatment, in combination with PerjetaIntravenous



Kadcyla trastuzumab-DM1 Hoffman-La Roche Early HER2-positive breast cancer adjuvant Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


veliparib AbbVie BRCA breast cancer Oral http://www.abbvie.com/research-innovation/pipeline.html

veliparib AbbVieNeoadjuvant treatment of triple negative breast

cancerOral http://www.abbvie.com/research-innovation/pipeline.html

xentuzumabBoehringer

Ingelheim

Metastatic breast cancer (oestrogen-receptor

positive)http://www.inoncology.com/trials/phaseII.html












http://www.abbvie.com/research-innovation/pipeline.html



Administration

Information Source




Endocrine CancerAvastin bevacizumab Genentech High-risk carcinoid Intravenous http://www.gene.com/medical-professionals/pipeline

Cometriq cabozantinib Exelixis Differentiated thyroid cancer Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


Cometriq cabozantinib Exelixis Medullary thyroid cancer Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


selumetinib AstraZeneca Differentiated thyroid cancer Oral https://www.astrazeneca.com/our-focus-areas/oncology.html

Zelboraf vemurafenib Genentech Papillary thyroid cancer, BRAF mutation positive Oral http://www.gene.com/medical-professionals/pipeline








Administration

Information Source




Gastrointestinal Cancer

avelumab EMD Serono Third line gastric cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

avelumab EMD Serono First line gastric cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

AZD6738 AstraZeneca Gastric cancer, in combination with lynparza https://www.astrazeneca.com/our-focus-areas/oncology.html

binimetinib Array BioPharmaBRAF-mutant colorectal cancer in combination

with encorafenib and cetuximabOral http://www.arraybiopharma.com/product-pipeline/binimetinib/

buparlisib Novartis Gastroesophageal junction cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

Cometriq cabozantinib Exelixis Advanced hepatocellular cancer Oral http://www.exelixis.com/pipeline

capmatinib Novartis Hepatocellular carcinoma Oral https://www.novartisoncology.com/about-us/our-pipeline

Cotellic cobimetinib Exelixis KRAS-mutant metastatic colorectal cancer Oral http://www.exelixis.com/pipeline/GDC_0973_xl518

Cotellic cobimetinibHoffmann-La

Roche

Third-line advanced or metastatic colorectal

cancer, in combination with TecentriqOral



codrituzumab Hoffman-La Roche Metastatic liver cancerhttp://www.roche.com/research_and_development/who_we_are_h


durvalumab +

tremelimumabAstraZeneca Gastric cancer Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca Metastatic pancreatic ductal carcinoma Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

E7820 Eisai Colorectal cancer Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf




http://www.emdserono.com/en/research/Pipeline/research.html




http://www.exelixis.com/pipeline






http://www.eisai.com/pdf/eir/erepo/epipeline.pdf


Administration

Information Source




encorafenib Array BioPharmaBRAF-mutant colorectal cancer in combination

with binimetinib and cetuximabOral

http://www.arraybiopharma.com/product-pipeline/encorafenib-

lgx818/

Xtandi enzalutamide Astellas Pharma Hepatocellular carcinoma Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

galunisertib Eli Lilly Hepatocellular Carcinoma Oral http://lillyoncologypipeline.com/clinical-phase/II

GS-5745 Gilead Sciences Gastric Cancer Subcutaneous http://www.gilead.com/research/pipeline

ipatasertib Genentech Gastric cancer Oral http://www.gene.com/medical-professionals/pipeline

Somatuline lanreotide Ipsen Pharma

Unresectable, well or moderately differentiated,

locally, advanced or metastatic

gastroenteropancreatic neuroendocrine tumors

Subcutaneoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m427065.htm

Lenvima lenvatinib Eisai Biliary tract cancer Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Lenvima lenvatinib Eisai Hepatocellular carcinoma Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Masivet masitinib AB ScienceAdvanced stage gastric or oesophageal

adenocarcinomaOral


oncology

Masivet masitinib AB Science Relapsed metastatic colorectal cancer Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Masivet masitinib AB Science Metastatic pancreatic cancer Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Masivet masitinib AB Science Relapsed metastatic liver cancer Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Masivet masitinib AB ScienceGastrointestinal stromal tumour, first-line

treatmentOral


oncology






http://www.gilead.com/research/pipeline














Administration

Information Source




Masivet masitinib AB ScienceGastrointestinal stromal tumour, second-line

treatmentOral


oncology

merestinib Eli Lilly Biliary tract cancer Oral http://lillyoncologypipeline.com/clinical-phase/II

MORAb-004 Eisai Colorectal cancer Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Vargatef nintedanibBoehringer

IngelheimColorectal cancer refractory to standard therapies Oral

http://www.inoncology.com/trials/colorectal_cancer/lume_colon1.h

tml

Abraxane paclitaxel Celgene Adjuvant therapy for pancreatic cancer Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

Vectibix panitumumab AmgenChemorefractory, wild-type KRAS exon 2

metastatic colorectal cancerIntravenous http://www.amgenpipeline.com/pipeline/

Keytruda pembrolizumab Merck Esophogeal cancer Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck Colorectal Cancer Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck Liver cancer Intravenous http://www.merck.com/research/pipeline/MerckPipeline.pdf

Keytruda pembrolizumab Merck Gastric cancer Intravenous http://www.merck.com/research/pipeline/home.html

Perjeta pertuzumab Genentech HER2-positive gastric cancer Intravenous http://www.gene.com/medical-professionals/pipeline

Perjeta pertuzumab Hoffman-La Roche Advanced HER2-positive gastric cancer Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Cyramza ramucirumab Eli Lilly

Metastatic colorectal cancer, in combination with

Folfiri, for patients whose disease has progressed

on a first line bevacizumab, oxaliplatin, and

fluoropyrimidine-containing regimen

Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m444496.htm

Cyramza ramucirumab Eli Lilly Gastric cancer - Phase 2 Intravenous http://lillyoncologypipeline.com/clinical-phase/II

Cyramza ramucirumab Eli Lilly Gastric cancer - Phase 3 Intravenous http://lillyoncologypipeline.com/clinical-phase/III







Changes for October 2016.xlsx




http://www.merck.com/research/pipeline/home.html










Administration

Information Source




Cyramza ramucirumab Eli Lilly Hepatocellular carcinoma Intravenous http://lillyoncologypipeline.com/clinical-phase/III

Stivarga regorafenib BayerMetastatic colorectal cancer after failure of

standard therapyOral

http://pharma.bayer.com/en/innovation-partnering/clinical-

trials/trial-finder/

Stivarga regorafenib BayerAsian patients with metastatic colorectal cancer

after failure of standard therapyOral



Stivarga regorafenib BayerPatients with metastatic coloretal cancer who

have progressed after standard therapyOral



Stivarga regorafenib Bayer Hepatocellular carcinoma Oralhttp://pharma.bayer.com/en/innovation-partnering/clinical-


Stivarga regorafenib Bayer Hepatocellular carcinoma (HCC) 2nd line Oralhttp://pharma.bayer.com/en/innovation-partnering/development-

pipeline/

Stivarga regorafenib BayerPatients with gastrointestinal tumours who have

progressed after standard therapyOral



Stivarga regorafenib Bayer

First-line treatment of metastatic colorectal

cancer with mFOLFOX6 in combination with

regorafenib

Oralhttp://pharma.bayer.com/en/innovation-partnering/clinical-


Stivarga regorafenib Bayer3rd-line or beyond treatment for gastrointestinal

stromal tumoursOral



tepotinib EMD Serono Hepatocellular cancer Oralhttp://www.emdserono.com/en/research/Pipeline/research.html

Added

vanucizumab Hoffman-La Roche Colorectal cancerhttp://www.roche.com/research_and_development/who_we_are_h






http://pharma.bayer.com/en/innovation-partnering/development-pipeline/

http://pharma.bayer.com/en/innovation-partnering/development-pipeline/

http://www.emdserono.com/en/research/Pipeline/research.html %0aAdded





Administration

Information Source




veliparib AbbVie Colorectal cancer Oral http://www.abbvie.com/research-innovation/pipeline.html





Administration

Information Source




Genitourinary Cancer

Zytiga abiraterone acetate JanssenMetastatic castration-resistant chemotherapy-

naïve prostate cancerOral

http://files.shareholder.com/downloads/JNJ/200945477x0x674691/

1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf

apalutamide JanssenPre-metastatic, castration-resistant prostate

cancerOral

http://files.shareholder.com/downloads/JNJ/2464592300x0x674691

/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf

apalutamide Janssen Metastatic hormone-sensitive prostate cancer Oralhttp://files.shareholder.com/downloads/JNJ/2464592300x0x674691


apalutamide Janssen Localized prostate cancer Oralhttp://files.shareholder.com/downloads/JNJ/2464592300x0x674691


Tecentriq atezolizumabHoffmann-La

Roche

First-line cisplatin-ineligible metastatic urothelial

carcinomaIntravenous



Tecentriq atezolizumab Genentech

For locally advanced or metastatic urothelial

carcinoma who have disease progression during

or following platinum-containing chem or have

disease progression within 12 mo's of

neoadjuvant or adjuvant treatment with platinum-

containing chemo


m501878.htm

Tecentriq atezolizumab Hoffman-La Roche Renal cell cancer, in combination with Avastin Intravenoushttp://www.roche.com/research_and_development/who_we_are_h





http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf







Administration

Information Source




Tecentriq atezolizumab Hoffman-La Roche Second-line urothelial bladder cancer Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Tecentriq atezolizumab Hoffman-La RocheMuscle-invasive bladder cancer, adjuvant

treatmentIntravenous



avelumab EMD Serono First line renal cell carcinoma Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

avelumab Pfizer First line urothelial cancer Intravenoushttp://www.pfizer.com/sites/default/files/product-


avelumab EMD Serono First line bladder cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

Inlyta axitinib PfizerRenal cell carcinoma adjuvant, in combination

with KeytrudaOral

http://www.pfizer.com/sites/default/files/product-


Cometriq cabozantinib ExelixisFor treatment of advanced renal cell carcinoma

following one prior anti-angiogenic therapyOral

http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m501878.htm

Cometriq cabozantinib Exelixis Metastatic renal cell cancer Oral http://www.exelixis.com/pipeline

Cometriq cabozantinib ExelixisAdvanced renal cell carcinoma: previously

untreated intermediate or poor-risk patientsOral



darolutamide BayerMetastatic castration sensitive prostate cancer,

incombination with standard ADT and docetaxel



durvalumab AstraZeneca Bladder Cancer Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html















http://www.exelixis.com/pipeline

../Changes for August 2016.xlsx

../Changes for August 2016.xlsx



Administration

Information Source




durvalumab +

tremelimumabAstraZeneca 1st-line bladder cancer Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

Xtandi enzalutamide Pfizer Non-metastatic castrate-resistant prostate cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Xtandi enzalutamide Astellas Pharma Metastatic hormone-sensitive prostate cancer Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Xtandi enzalutamide Astellas PharmaNon-metastatic castration-resistant prostate

cancerOral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Xtandi enzalutamide Astellas PharmaProstate cancer in patients with non-metastatic

biochemical recurrenceOral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Xtandi enzalutamide PfizerNon-metastatic high-risk hormone-sensitive

prostate cancerOral



Xtandi enzalutamide Pfizer Metastatic hormone-sensitive prostate cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Halaven eribulin Astellas Pharma

For the treatment of patients with unresectable

or metastatic liposarcoma who have received a

prior anthracycline-containing regimen.


m279174.htm

ipatasertib Genentech Prostate cancer Oral http://www.gene.com/medical-professionals/pipeline

Lenvima lenvatinib Eisai First-line renal cell carcinoma Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Lenvima

lenvatinib, in

combination with

everolimus

EisaiFor treatment of advanced renal cell carcinoma

following one prior anti-angiogenic therapyOral


m501878.htm

LY3023414 Eli Lilly Prostate cancer Oral http://lillyoncologypipeline.com/clinical-phase/II














Administration

Information Source




Masivet masitinib AB ScienceMetastatic hormone refractory prostate cancer in

progression after first line of treatmentOral


oncology

Keytruda pembrolizumab Merck Prostate cancer Intravenous http://www.merck.com/research/pipeline/MerckPipeline.pdf

Keytruda pembrolizumab Merck Bladder cancer Intravenous http://www.merck.com/research/pipeline/home.html

Cyramza ramucirumab Eli Lilly Bladder cancer Intravenous http://lillyoncologypipeline.com/clinical-phase/III

Stivarga regorafenib BayerPreviously untreated patients with metastatic or

unresectable renal cell carcinomaOral



savolitinib/ volitinib AstraZeneca Papillary renal cell carcinoma https://www.astrazeneca.com/our-focus-areas/oncology.html

Sutent sunitinib Pfizer Renal cell carcinoma adjuvant Oralhttp://www.pfizer.com/sites/default/files/product-


TAK-228 Takeda Endrometrial Cancer Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


TAK-228 Takeda Renal Cancer Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


volasertibBoehringer

Ingelheim

Urothelial cancer (of the bladder, uterus or renal

pelvis)Intravenous http://www.inoncology.com/trials/phaseII.html










Administration

Information Source




Gynecological Cancer

avelumab EMD Serono Platinum resistant/refractory ovarian cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

avelumab EMD Serono First line ovarian cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

AZD1775 AstraZenecaOvarian cancer, in combination with

chemotherapyhttps://www.astrazeneca.com/our-focus-areas/oncology.html

Avastin bevacizumab Genentech First-line metastatic ovarian cancer Intravenous http://www.gene.com/medical-professionals/pipeline

Avastin bevacizumab Hoffman-La Roche Relapsed platinum-sensitive ovarian cancer Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Cometriq cabozantinib Exelixis Endometrial cancer Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


Cometriq cabozantinib Exelixis High-grade uterine sarcoma Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


farletuzumab Eisai Platinum-sensitive ovarian cancer Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Lenvima lenvatinib Eisai Endometrial cancer Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Keytruda pembrolizumab Merck Ovarian Cancer Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck Renal cancer Intravenous http://www.merck.com/research/pipeline/home.html

ralimetinib Eli Lilly Ovarian cancer Oral http://lillyoncologypipeline.com/clinical-phase/II

Yondelis trabectedin Janssen Relapsed ovarian cancer Intravenoushttp://files.shareholder.com/downloads/JNJ/2464592300x0x674691


veliparib AbbVie Ovarian cancer Oral http://www.abbvie.com/research-innovation/pipeline.html














Administration

Information Source





Ingelheim

Ovarian cancer (epithelial ovarian cancer,

peritoneal carcinoma or fallopian tube carcinoma)Intravenous http://www.inoncology.com/trials/phaseII.html





Administration

Information Source




Head and Neck Cancer

Giotrif afatinibBoehringer

Ingelheim

Recurrent and/or metastatic head and neck

squamous cell carcinoma who have progressed

after platinum‑based therapy

Oral http://www.inoncology.com/trials/head_and_neck_cancer.html

alpelisib Novartis Head and neck squamous cell carcinoma Oral https://www.novartisoncology.com/about-us/our-pipeline

avelumab Pfizer Squamous head and neck cancer Intravenoushttp://www.pfizer.com/sites/default/files/product-


buparlisib Novartis Head and neck cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

buparlisib Novartis Glioblastoma multiforme Oral https://www.novartisoncology.com/about-us/our-pipeline

durvalumab AstraZeneca Squamous cell carcinoma of the head and neck Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca 1st-line SCCHN Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca 2nd-line SCCHN (PD-L1 negative) Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca 2nd-line SCCHN Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

Masivet masitinib AB Science Relapsed metastatic head and neck cancer Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Nimoral nimorazole Azanta A/S

First-line platinum-resistent head and neck

squamous cell carcinoma, versus conventional

radiation therapy

Oral http://www.azanta.com/pipeline.aspx














http://www.azanta.com/pipeline.aspx


Administration

Information Source




Nimoral nimorazole Azanta A/SHead and neck squamous cell carcinoma, first line

accelerated chemo-radiation therapy (CRT)Oral http://www.azanta.com/pipeline.aspx

Nimoral nimorazole Azanta A/SFirst-line head and neck squamous cell carcinoma,

versus accelerated chemo-radiation therapyOral http://www.azanta.com/pipeline.aspx

Nimoral nimorazole Azanta A/S

Head and neck squamous cell carcinoma, second

line re-irradiation, accelerated or conventinal

chemo-radiation therapy (CRT)

Oral http://www.azanta.com/pipeline.aspx

Ibrance palbociclib Pfizer Squamous cell carcinoma of the head and neck Oralhttp://www.pfizer.com/sites/default/files/product-


Keytruda pembrolizumab Merck Nasopharyngeal cancer Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck

Recurrent or metastatic head and neck squamous

cell carcinoma with disease progression on or

after platinum-containing chemotherapy


m515627.htm




http://www.azanta.com/pipeline.aspx







Administration

Information Source




Leukemia

acalabrutinib AstraZeneca First-line chronic lymphocytic leukemia Oral https://www.astrazeneca.com/our-focus-areas/oncology.html

acalabrutinib AstraZenecaHigh-risk relapsed/refractory chronic lymphocytic

leukemiaOral https://www.astrazeneca.com/our-focus-areas/oncology.html

AG-221 Celgene Acute myeloid leukemia https://www.celgene.com/content/uploads/product-pipeline.pdf

ASP2215 Astellas Pharma Acute myeloid leukemia Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Vidazaazacitidine for

injectionCelgene Acute myeloid leukemia (20-30% blasts) Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf


injectionCelgene Acute myeloid leukemia (>30% blasts Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf


injectionCelgene

Post-induction acute myeloid leukemia

maintenanceIntravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

BI 836826Boehringer

IngelheimChronic lymphocytic leukemia http://www.inoncology.com/trials/phaseII.html

Blincyto blinatumomab Amgen

Relapsed/refractory Philadelphia chromosone-

positive (Ph+) and minimal residual disease of

acute lymphoblastic leukemia

Intravenous http://www.amgenpipeline.com/pipeline/

Bosulif bosutinib PfizerAdult patients with newly diagnosed chronic

myelogenous leukemia, versus imatinibOral














Administration

Information Source




durvalumab Celgene Acute myeloid leukemia (AML) Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

duvelisib AbbVie Chronic lymphocytic leukemia Oralhttp://www.abbvie.com/content/dam/abbviecorp/us/desktop/onco

logy/oncology-pipeline.jpg

entospletinib Gilead Sciences Hematological Malignancies Oral http://www.gilead.com/research/pipeline

entospletinib Gilead Sciences Acute Myeloid Leukemia Oral http://www.gilead.com/research/pipeline

Imbruvica ibrutinib JanssenFrontline chronic lymphocytic leukemia (young

and fit), in combinaction with rituximabOral



Imbruvica ibrutinib Janssen

Relapsed/refractory chronic lymphocytic

leukemia in combination with bendamustine and

rituximab

Oralhttp://files.shareholder.com/downloads/JNJ/2464592300x0x674691


Imbruvica ibrutinib JanssenFrontline chronic lymphocytic leukemia, in

combination with obinutuzumabOral

http://files.shareholder.com/downloads/JNJ/200945477x0x674691/


Imbruvica ibrutinib AbbVie Acute myeloid leukemia (AML) Oral http://www.abbvie.com/research-innovation/pipeline.html

idasanutlinHoffmann-La

RocheAcute myeloid leukemia



Zydelig Idelalisib Gilead Sciences Relapsed refractory chronic lymphocytic leukemia Oral http://www.gilead.com/research/pipeline

inotuzumab

ozogamicinPfizer Acute lymphocytic leukemia Intravenous



inotuzumab

ozogamicinPfizer Acute lymphocytic leukemia Intravenous



















Administration

Information Source




LCL161 Novartis Leukemia https://www.novartisoncology.com/about-us/our-pipeline

Revlimid lenalidomide Celgene Second-line chronic lymphocitic leukemia Oral http://www.celgene.com/content/uploads/product-pipeline.pdf

midostaurin Novartis Acute myeloid leukemia Oral https://www.novartisoncology.com/about-us/our-pipeline

moxetumomab

pasudotoxAstraZeneca Hairy cell leukaemia Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

Gazyva obinutuzumab Genentech Front-line chronic lymphocytic leukemia Intravenous http://www.gene.com/medical-professionals/pipeline

Arzerra ofatumumab Novartis

For extended treatment of patients who are in

complete or partial response after at least two

lines of therapy for recurrent or progressive

chronic lymphocytic leukemia (CLL)


m279174.htm

pevonedistat Takeda High-risk myelodysplastic syndromes Intravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-


polatuzumab vedotinHoffmann-La

RocheHematological malignancies



Iclusig ponatinibAriad

PharmaceuticalsChronic myeloid leukemia (2nd line) Oral http://www.ariad.com/research-development/pipeline/

Rituxan rituximabHoffmann-La

RocheChronic lymphocytic leukemia Subcutaneous



TAK-659 Takeda Acute myeloid leukemiahttps://www.takedaoncology.com/content/assets/Takeda-Global-


vadastuximab talirine Seattle Genetics Frontline older acute myeloid leukemia Intravenous http://www.seattlegenetics.com/pipeline





http://www.celgene.com/content/uploads/product-pipeline.pdf







http://www.ariad.com/research-development/pipeline/


Administration

Information Source




vadastuximab talirine Seattle GeneticsRelapsed acute myeloid leukemia pre/post allo-

transplantIntravenous http://www.seattlegenetics.com/pipeline

Venclexta venetoclax AbbVie Acute myeloid leukemia Oral http://www.abbvie.com/research-innovation/pipeline.html

Venclexta venetoclax AbbVie Chronic lymphocytic leukemia Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m279174

Venclexta venetoclax Hoffman-La RocheFrontline chronic lymphocytic leukemia, in

combination with GazyvaOral



Venclexta venetoclax Hoffman-La RocheRealpsed/refractory chronic lymphocytic

leukemia, in combination with rituximabOral




IngelheimAcute myeloid leukemia Intravenous

http://www.boehringer-

ingelheim.com/research_development/drug_discovery/pipeline.htm

l




http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174

http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174





http://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html




Administration

Information Source




Lung Cancerabemaciclib Eli Lilly Non-small cell lung cancer Oral http://lillyoncologypipeline.com/clinical-phase/III

abemaciclib Eli Lilly Squamous non-small cell lung cancer Oral http://lillyoncologypipeline.com/clinical-phase/II

abemaciclib Eli Lilly Non-small cell lung cancer Oral http://lillyoncologypipeline.com/clinical-phase/II


Ingelheim

Non-small cell lung cancer after failure of erlotinib

or gefitinibOral http://www.inoncology.com/trials/lung_cancer.html


Ingelheim

Patients with non-small cell lung cancer (NSCLC)

who had failed at least one line of chemotherapy

and erlotinib or gefitinib treatment

Oral http://www.inoncology.com/trials/lung_cancer.html


Ingelheim

Stage IIIB or IV adenocarcinoma of the lung

harbouring an epidermal growth factor receptor

(EGFR) activating mutation



Ingelheim

First‑line treatment of patients with common

epidermal growth factor receptor (EGFR)

mutations (del19/L858R) and advanced

adenocarcinoma of the lung



Ingelheim

Advanced squamous cell carcinoma of the lung as

second-line therapy following first-line platinum-

based chemotherapy

Oral http://www.inoncology.com/trials/lung_cancer/lux-lung8.html

Alecensa alectinib Hoffman-La RocheALK+ non-small cell lung cancer, first-line

treatmentOral



Alecensa alectinib Genentech ALK+ metastatic non-small cell lung cancer Oral http://www.gene.com/medical-professionals/pipeline













Administration

Information Source




alisertib Takeda Small cell lung cancer Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


ASP8273 Astellas Pharma Non-small cell lung cancer Oral https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf


Roche

First-line non-squamous non-small cell lung

cancer, in combination with chemotherapyIntravenous



Tecentriq atezolizumab Hoffman-La Roche

Metastatic non-small cell lung cancer whose

disease progressed during or following platinum-

containing chemotherapy


m525780.htm

Tecentriq atezolizumab Hoffman-La Roche


cancer, in combination with chemotherapy, with

or without Avastin

Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Tecentriq atezolizumab Hoffman-La Roche Second-line non-small cell lung cancer Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


Tecentriq atezolizumab Hoffman-La RocheFirst-line non-squamous and squamous non-small

cell lung cancer, PDL1-selected patientsIntravenous




RocheFirst-line squamous non-small cell lung cancer Intravenous




Roche


cancer, in combination with chemotherapy and

pemetrexed

Intravenoushttp://www.roche.com/research_and_development/who_we_are_h



RocheFirst line extensive-stage small cell lung cancer Intravenous






















Administration

Information Source




Tecentriq atezolizumab Hoffman-La Roche Non-small cell lung cancer, adjuvant treatment Intravenoushttp://www.roche.com/research_and_development/who_we_are_h


avelumab EMD Serono First line non-small cell lung cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/research.html

Added

avelumab Pfizer Non-small cell lung cancer Intravenoushttp://www.pfizer.com/sites/default/files/product-


avelumab EMD Serono Second line non-small cell lung cancer Intravenous http://www.emdserono.com/en/research/Pipeline/research.html

Avastin bevacizumab Genentech Adjuvant non-small cell lung cancer Intravenous http://www.gene.com/medical-professionals/pipeline

BI 1361849Boehringer

IngelheimNon-small cell lung cancer http://www.inoncology.com/trials/phaseII.html

brigatinibAriad

Pharmaceuticals

locally advanced or metastatic NSCLC who test

positive for the ALK oncogene and who were

previously treated with crizotinib

Oralhttp://www.ariad.com/research-development/brigatinib/clinical-

trials/

brigatinibAriad

Pharmaceuticals

ALK-positive locally advanced or metastatic non-

small cell lung cancer (NSCLC) who have not

previously been treated with an ALK inhibitor

Oralhttp://www.ariad.com/research-development/brigatinib/clinical-

trials/

Cometriq cabozantinib Exelixis Non-small cell lung cancer: RET rearranged Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


Cometriq cabozantinib ExelixisNon-small cell lung cancer: metastases to the

brainOral



Cometriq cabozantinib Exelixis Non-small cell lung cancer: EGFR wild-type Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli











http://www.ariad.com/research-development/brigatinib/clinical-trials/




Changes for November 2016.xlsx

Changes for November 2016.xlsx


Administration

Information Source




capmatinib Novartis Non-small cell lung cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

Cotellic cobimetinib Exelixis NSCLC Oral http://www.exelixis.com/pipeline/GDC_0973_xl518

Xalkori crizotinib Pfizer

Treatment of patients with metastatic non-small

cell lung cancer (NSCLC) whose tumors are ROS1-

positive


m279174.htm

dacomitinib Pfizer First-line EGFR-mutant non-small cell lung cancer Oralhttp://www.pfizer.com/sites/default/files/product-


Xgeva denosumab AmgenPrevention of skeletal-related events in patients

with non-small cell lung cancerSubcutaneous http://www.amgenpipeline.com/pipeline/

durvalumab AstraZeneca Stage III NSCLC Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca 1st-line NSCLC Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

durvalumab +

tremelimumabAstraZeneca 3rd-line NSCLC Intravenous https://www.astrazeneca.com/our-focus-areas/oncology.html

EGF816 Novartis Non-small cell lung cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

emibetuzumab Eli Lilly Non-small cell lung cancer Intravenous http://lillyoncologypipeline.com/clinical-phase/II

Halaven eribulin Eisai Non-small cell lung cancer Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Tarceva erlotinib Astellas Pharma

First-line treatment of metastatic non-small cell

lung cancer patients whose tumors have

epidermal growth factor receptor exon 19

deletions or exon 21 (L858R) substitution

mutations


m352317.htm



















Administration

Information Source




Tarceva erlotinib Genentech

Non-small cell lung cancer to limit use to patients

whose tumors have specific epidermal growth

factor receptor (EGFR) mutations


m525739.htm

farletuzumab Eisai Non-small cell lung cancer Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Iressa gefitinib AstraZeneca

For the treatment of patients with metastatic non-

small cell lung cancer (NSCLC) whose tumors have

epidermal growth factor receptor (EGFR) exon 19

deletions or exon 21 (L858R) substitution

mutations as detected by an FDA-approved test.


m454692.htm

Lenvima lenvatinib Eisai Non-small cell lung cancer (RET translocations) Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Lenvima lenvatinib EisaiThird-line monotherapy for non-small cell lung

cancerOral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

lorlatinib Pfizer ALK non-small cell lung cancer Oralhttp://www.pfizer.com/sites/default/files/product-


LY3023414 Eli Lilly Non-small cell lung cancer Oral http://lillyoncologypipeline.com/clinical-phase/II

necitumumab Eli Lilly Squamous non-small cell lung cancer Intravenous http://lillyoncologypipeline.com/clinical-phase/II


Ingelheim

Advanced or recurrent non‑small cell lung cancer

patients after failure of first‑line therapy, in

combination with pemetrexed

















Administration

Information Source





Ingelheim

Stage IIIB/IV or recurrent non‑small cell lung

cancer (NSCLC) after failure of first‑line

chemotherapy, incombination with docetaxel



486)Celgene Advanced non-small cell lung cancer Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Tagrisso osimertinib AstraZeneca Brain metastases in advanced EGRFm NSCLC Oral https://www.astrazeneca.com/our-focus-areas/oncology.html

Tagrisso osimertinib AstraZeneca Advanced EGFRm NSCLC Oral https://www.astrazeneca.com/our-focus-areas/oncology.html

Abraxane paclitaxel Celgene Advanced non-small cell lung cancer (first-line) Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

prexasertib Eli Lilly Small cell lung cancer Intravenous http://lillyoncologypipeline.com/clinical-phase/II

Cyramza ramucirumab Eli Lilly Non-small cell lung cancer - Phase 3 Intravenous http://lillyoncologypipeline.com/clinical-phase/III

Cyramza ramucirumab Eli Lilly Non-small cell lung cancer - Phase 2 Intravenous http://lillyoncologypipeline.com/clinical-phase/II

Cyramza ramucirumab Eli Lilly

Metastatic non-small cell lung cancer with disease

progression on or after platinum-based

chemotherapy, in combination with docetaxel


m426735.htm

ribociclib Novartis Non-small cell lung cancer Oral https://www.novartisoncology.com/about-us/our-pipeline

Rova-Trovalpituzumab

tesirineAbbVie

Second-line treatment for extensive-stage small

cell lung cancer, in combination with nivolumab

and ipilimumab


TAK-117 Takeda Non-small cell lung cancer Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-












Administration

Information Source




taselisib Hoffman-La Roche Second-line squamous non-small cell lung cancer Oralhttp://www.roche.com/research_and_development/who_we_are_h


tepotinib EMD Serono Non-small cell lung cancer Oral http://www.emdserono.com/en/research/Pipeline/research.html

Kadcylatrastuzumab

emtansineHoffman-La Roche

HER2-positive advanced non-small cell lung

cancerIntravenous



veliparib AbbVie Squamous non-small cell lung cancer Oral http://www.abbvie.com/research-innovation/pipeline.html

veliparib AbbVie Non-squamous non-small cell lung cancer Oral http://www.abbvie.com/research-innovation/pipeline.html


IngelheimAdvanced non-small cell lung cancer Intravenous http://www.inoncology.com/trials/phaseII.html












Administration

Information Source




Lymphoma and Myeloma

acalabrutinib AstraZeneca B-cell malignancy https://www.astrazeneca.com/our-focus-areas/oncology.html

Beleodaq belinostat SpectrumRelapsed or refractory peripheral T-cell

lymphomaIntravenous


m403960.htm

BI 836826Boehringer

IngelheimNon-Hodgkin lymphoma http://www.inoncology.com/trials/phaseII.html

Adcetris brentuximab Vedotin Seattle GeneticsFrontline diffuse large B-cell lymphoma (rituximab

+ chemotherapy +/− brentuximab vedotin)Intravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab Vedotin Seattle Genetics

Relapsed CD30-expressing diffuse large B-cell

lymphoma (rituximab + bendamustine +/−

brentuximab vedotin

Intravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab vedotin Seattle GeneticsFrontline CD30-expressing mature T-cell

lymphomas, in combination with chemotherapyIntravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab vedotin Seattle Genetics CD30-expressing cutaneous T-cell lymphoma Intravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab vedotin Seattle Genetics Frontline Hodgkin lymphoma in patients 60+ Intravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab vedotin Seattle GeneticsSecond-line Hodgkin lymphoma, in combination

with nivolumabIntravenous http://www.seattlegenetics.com/pipeline

Adcetris brentuximab vedotin Seattle GeneticsRelapsed non-Hodgkin lymphoma, in combination

with nivolumabIntravenous http://www.seattlegenetics.com/pipeline







http://www.seattlegenetics.com/pipeline






Administration

Information Source




Adcetris brentuximab vedotin Seattle GeneticsFrontline Hodgkin lymphoma, in combination with

chemotherapyIntravenous http://www.seattlegenetics.com/pipeline

Kyprolis carfilzomib AmgenNewly diagnosed multipe myeloma, in

combination with melphalan and prednisoneIntravenous http://www.amgenpipeline.com/pipeline/

CD 19 CAR-T

(JCAR015)Celgene Acute Lymphocytic Leukemia https://www.celgene.com/content/uploads/product-pipeline.pdf

copanlisib BayerRelapsed indolent non-Hodgkin's lymphoma, in

combination with rituximabhttp://www.chronostrials.com/

copanlisib BayerRituximab-refractory indolent non-Hodgkin's

lymphomahttp://www.chronostrials.com/

copanlisib Bayer

Relapsed indolent non-Hodgkin's lymphoma, in

combination with standard

immunochemotherapy

http://www.chronostrials.com/

copanlisib Bayer Mantle cell lymphoma http://www.chronostrials.com/

copanlisib BayerRelapsed, indolent or aggressive non-Hodgkin's

lymphomashttp://www.chronostrials.com/

copanlisib Bayer Diffuse large B-cell lymphoma http://www.chronostrials.com/

Darzalex daratumumab Janssen Double refractory multiple myeloma Intravenoushttp://files.shareholder.com/downloads/JNJ/2464592300x0x674691


Darzalex daratumumab Janssen

Frontline multiple myeloma transplant-ineligible

patients, in combination with bortezomib,

melphalan and prednisone

Intravenoushttp://files.shareholder.com/downloads/JNJ/200945477x0x674691/











Administration

Information Source




Darzalex daratumumab JanssenRelapsed/refractory multiple myeloma, in

combination with bortezomib/dexamethasoneIntravenous


m530249.htm


Frontline multiple myeloma transplant-eligible

patients, in combination with velcade,

thalidomide and dexamethasome



Darzalex daratumumab JanssenRelapsed/refractory multiple myeloma, in

combination with lenalidomide/dexamethasoneIntravenous


m530249.htm


Frontline multiple myeloma transplant-ineligible

patients, in combination with lenalidomide and

low-dose dexamethasone



Aranesp darbepoetin alfa Amgen Low risk myelodysplastic syndromes Subcutaneous http://www.astrazeneca.com/Research/Our-pipeline-summary

denintuzumab

mafodotinSeattle Genetics

Relapsed diffuse large B-cell lymphoma (rituximab

+ chemotherapy +/− SGN-CD19A)Intravenous http://www.seattlegenetics.com/pipeline

denintuzumab

mafodotinSeattle Genetics

Frontline diffuse large B-cell lymphoma, in

combination with chemotherapy) (planned)Intravenous http://www.seattlegenetics.com/pipeline

Xgeva denosumab AmgenPrevention of skeletal-related events in patients

with multiple myelomaSubcutaneous http://www.amgenpipeline.com/pipeline/

duvelisib AbbVie Indolent non-Hodgkin's lymphoma Oralhttp://www.abbvie.com/content/dam/abbviecorp/us/desktop/onco

logy/oncology-pipeline.jpg

Empliciti elotuzumab AbbVie Multiple myeloma treatment naïve Intravenous http://www.abbvie.com/research-innovation/pipeline.html










http://www.astrazeneca.com/Research/Our-pipeline-summary






Administration

Information Source




filanesib Array BioPharma Relapsed and refractory multiple myeloma Intravenous http://www.arraybiopharma.com/product-pipeline/filanesib/

filanesib Array BioPharmaRelapsed and refractory multiple myeloma in

combination with carfilzomibIntravenous http://www.arraybiopharma.com/product-pipeline/filanesib/

Imbruvica ibrutinib JanssenMarginal zone lymphoma in patients who have

received at least one prior therapyOral



Imbruvica ibrutinib AbbVie Diffuse large B-cell lymphoma Oral http://www.abbvie.com/research-innovation/pipeline.html

Imbruvica ibrutinib AbbVie Marginal zone lymphoma (MZL) Oral http://www.abbvie.com/research-innovation/pipeline.html

Imbruvica ibrutinib AbbVie Follicular lymphoma Oral http://www.abbvie.com/research-innovation/pipeline.html


Relapsed/refractory indolent non-Hodgkin's

lymphoma, in combination with bendamustine

and rituximab or R-CHOP

Oralhttp://files.shareholder.com/downloads/JNJ/200945477x0x674691/



Treatment naive patients with mantle cell

lymphoma, in combination with Bendamustine

and Rituximab



Imbruvica ibrutinib AbbVie Multiple myeloma Oral http://www.abbvie.com/research-innovation/pipeline.html

Imbruvica ibrutinib JanssenPatients with mantle cell lymphoma who have

received at least one prior therapyOral


m374857.htm















Administration

Information Source





Newly diagnosed non-germinal centre B-cell

subtype of diffuse large B-cell lymphoma, in

combination with R-CHOP



Imbruvica ibrutinib AbbVie Follicular lymphoma Oral http://www.abbvie.com/research-innovation/pipeline.html

isatuximab Sanofi Multiple Myeloma Intravenous http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx

Ninlaro ixazomib Takeda

Maintenance therapy in patients with newly

diagnosed multiple myeloma not treated with

stem cell transplant

Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


Ninlaro ixazomib Takeda

Maintenance therapy in patients with newly

diagnosed multiple myeloma following

autologous stem cell transplant

Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


Ninlaro ixazomib Takeda Previously untreated multiple myeloma Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


Ninlaro ixazomib Takeda Relapsed or refractory primary (AL) amyloidosis Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


Ninlaro ixazomib Takeda Lymphoma Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-


LCL161 Novartis Multiple myeloma https://www.novartisoncology.com/about-us/our-pipeline

Revlimid lenalidomide Celgene Relapsed/refractory indolent lymphoma Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Revlimid lenalidomide Celgene First-line follicular lymphoma Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Revlimid lenalidomide Celgene Diffuse large B-cell lymphoma Oral http://www.celgene.com/content/uploads/product-pipeline.pdf






http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx






Administration

Information Source




Revlimid lenalidomide Celgene Relapsed/refractory multiple myeloma Oral https://www.celgene.com/content/uploads/product-pipeline.pdf

Revlimid lenalidomide Celgene

Mantle cell lymphoma whose disease has

relapsed or progressed after two prior therapies,

one of which included bortezomid


m355438.htm

Revlimid lenalidomide CelgeneFirst-line diffuse large B-cell lymphoma (ABC-

subtype)Oral http://www.celgene.com/content/uploads/product-pipeline.pdf

Masivet masitinib AB Science Relapsed multiple myeloma Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Masivet masitinib AB Science Relapsed peripheral T-cell lymphoma Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

Opdivo nivolumabBristol-Myers

Squibb

For patients with classical Hodgkin lymphoma

(cHL) that has relapsed or progressed after

autologous hematopoietic stem cell

transplantation (HSCT) and post-transplantation

brentuximab vedotin (Adcetris)


m501412.htm

Gazyva obinutuzumab Genentech Front-line indolent non-Hodgkin's lymphoma Intravenous http://www.gene.com/medical-professionals/pipeline

Gazyva obinutuzumab Genentech Refractory indolent non-Hodgkin's lymphoma Intravenous http://www.gene.com/medical-professionals/pipeline

Gazyva obinutuzumab Genentech Diffuse large B-cell lymphoma Intravenous http://www.gene.com/medical-professionals/pipeline

Gazyva obinutuzumab Hoffman-La Roche Front-line indolent non-Hodgkin's lymphoma Intravenoushttp://www.roche.com/research_and_development/who_we_are_h




















Administration

Information Source




Farydak panobinostat Novartis

Multiple myeloma, in combination with

bortezomib and dexamethasone, for patients who

have received at least two prior regimens

including bortezomib and an immunomodulatory

agent


m435339.htm

Keytruda pembrolizumab Merck Multiple myeloma Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck Hodgkin Lymphoma Intravenous http://www.merck.com/research/pipeline/home.html

Keytruda pembrolizumab Merck Primary mediastinal primary B-cell lymphoma Intravenous http://www.merck.com/research/pipeline/home.html

polatuzumab vedotin GenentechNon-Hodgkin's lymphoma and diffuse large B-cell

lymphomaIntravenous http://www.gene.com/medical-professionals/pipeline

Istodax romidepsin Celgene First-line peripheral T-cell lymphoma Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

Istodaxromidepsin for

injectionCelgene Cutaneous T-cell lymphoma Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

TAK-659 Takeda Lymphomahttps://www.takedaoncology.com/content/assets/Takeda-Global-


Thalomid thalidomide Celgene Newly diagnosed multiple myeloma https://www.celgene.com/content/uploads/product-pipeline.pdf

Venclexta venetoclax AbbVie Non-hodgkin lymphoma Oral http://www.abbvie.com/research-innovation/pipeline.html

Venclexta venetoclax Hoffman-La Roche Front-line diffuse large B-cell lymphoma Oralhttp://www.roche.com/research_and_development/who_we_are_h


Venclexta venetoclax Hoffman-La RocheRelapsed/refractory follicular lymphoma, in

combination with rituximabOral

















Administration

Information Source




Venclexta venetoclaxHoffmann-La

RocheRelapsed or refractory multiple myeloma Oral



Venclexta venetoclax AbbVie Diffuse large B-cell lymphoma Oral http://www.abbvie.com/research-innovation/pipeline.html

Venclexta venetoclax AbbVie Multiple myeloma Oral http://www.abbvie.com/research-innovation/pipeline.html







Administration

Information Source




Melanomaabemaciclib Eli Lilly Melanoma Oral http://lillyoncologypipeline.com/clinical-phase/II

avelumab Pfizer Melanoma Intravenoushttp://www.pfizer.com/sites/default/files/product-


binimetinib Array BioPharma NRAS-mutant melanoma Oral http://www.arraybiopharma.com/product-pipeline/binimetinib/

binimetinib Array BioPharmaBRAF-mutant melanoma in combination with

encorafenibOral http://www.arraybiopharma.com/product-pipeline/binimetinib/

Cotellic cobimetinib Exelixis Melanoma Oral http://www.exelixis.com/pipeline/GDC_0973_xl518

encorafenib Array BioPharma BRAF V600 mutant melanoma Oralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-

lgx818/

Lenvima lenvatinib Eisai Melanoma Oral http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Masivet masitinib AB Science Metastatic melanoma with JM mutation of c-KIT Oralhttp://www.ab-science.com/en/human-medicine/masitinib-in-

oncology

MORAb-004 Eisai Melanoma Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

Imlygictalimogene

laherparepvecAmgen

Mid to late-stage metastatic melanoma in

combination with KeytrudaSubcutaneous http://www.amgenpipeline.com/pipeline/

Zelboraf vemurafenib Hoffman-La Roche Adjuvant melanoma, BRAF mutation positive Oralhttp://www.roche.com/research_and_development/who_we_are_h






http://www.arraybiopharma.com/product-pipeline/binimetinib/

http://www.arraybiopharma.com/product-pipeline/binimetinib/









Administration

Information Source




Neurological Cancer

ABT-414 AbbVie Glioblastoma Multiforme http://www.abbvie.com/research-innovation/pipeline.html

Avastin bevacizumab Genentech First-line glioblastoma multiforme Intravenous http://www.gene.com/medical-professionals/pipeline

Unituxin dinutuximabUnited

Therapeutics

High-risk neuroblastoma in combination with GM-

CSF, IL-2 and 13-cis-retinoic acid, for pediatric

patients who have achieved at least a partial

response to prior first-line multiagent,

multimodality therapy


m437480.htm

galunisertib Eli Lilly Glioma Oral http://lillyoncologypipeline.com/clinical-phase/II









Administration

Information Source




SarcomaHalaven eribulin Eisai Advanced soft tissue sarcoma Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

MORAb-004 Eisai Soft tissue sarcoma Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

olaratumab Eli Lilly

Soft tissue sarcoma not amenable to curative

treatment with radiotherapy or surgery and with

a histologic subtype for which an anthracycline-

containing regimen is appropriate


m526087.htm









Administration

Information Source




Otheramatuximab Eisai Mesothelioma Intravenous http://www.eisai.com/pdf/eir/erepo/epipeline.pdf

anetumumab

ravtansineBayer Malignant pleural mesothelioma



avelumab Pfizer Second-line metastatic merkel cell carcinoma Intravenoushttp://www.pfizer.com/sites/default/files/product-


avelumab EMD Serono Merkel cell carcinoma Intravenous http://www.emdserono.com/en/research/Pipeline/research.html


injectionCelgene Myelodysplastic syndromes Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

Xgeva denosumab Amgen

Adults and skeletally-mature adolescents with

giant cell tumor of bone that is unresectable or

where surgical resection is likely to reult in severe

morbidity

Subcutaneoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/uc

m356667.htm

Revlimid lenalidomide Celgene Myelodysplastic syndrome - deletion 5q Oral http://www.celgene.com/content/uploads/product-pipeline.pdf

luspatercept Celgene Myleodysplastic syndrome Subcutaneous https://www.celgene.com/content/uploads/product-pipeline.pdf

momelotinib Gilead Sciences Myelofibrosis Oral http://www.gilead.com/research/pipeline


486)Celgene Lower-risk myelodysplastic syndrome Oral https://www.celgene.com/content/uploads/product-pipeline.pdf


486)Celgene

Myelodysplastic syndrome - post

hypomethylating agent failureOral https://www.celgene.com/content/uploads/product-pipeline.pdf















Administration

Information Source




SAR439684 Sanofi Advanced cutaneous squamous cell carcinoma http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx

Odomzo sonidegib Novartis

For the treatment of patients with locally

advanced basal cell carcinoma (BCC) that has

recurred following surgery or radiation therapy,

or those who are not candidates for surgery or

radiation therapy.


m455865.htm

Cometriq cabozantinib Exelixis Advanced soft tissue carcinoma Oralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Cli


durvalumab Celgene Myleodysplastic syndrome Intravenous https://www.celgene.com/content/uploads/product-pipeline.pdf

Tagrisso osimertinib AstraZeneca Leptomeningeal metastases Oral https://www.astrazeneca.com/our-focus-areas/oncology.html

vadastuximab talirine Seattle GeneticsFrontline myelodysplastic syndrome, in

combination with hypomethylating agentsIntravenous http://www.seattlegenetics.com/pipeline


IngelheimMyelodysplastic syndrome Intravenous http://www.inoncology.com/trials/phaseII.html








Cancer Drug Pipeline Information for Patient Advocacy … advised that the information contained in...

Documents

Transcript of Cancer Drug Pipeline Information for Patient Advocacy … advised that the information contained in...